Pharming Group joins Euronext AMX MidCap index

Pharming Group N.V. filed a Form 6-K to report that it has been promoted from the Euronext AScX (Small Cap) to the Euronext AMX (MidCap) index, effective September 22, 2025.

Rhea-AI Filing Summary

Pharming Group N.V. filed a Form 6-K to report that it has been promoted from the Euronext AScX (Small Cap) to the Euronext AMX (MidCap) index, effective September 22, 2025. The AMX index includes 25 companies selected by Euronext Amsterdam based on free-float market capitalization and liquidity, and this move marks Pharming’s return to the AMX.

The company describes this promotion as a reflection of its strong financial and pipeline growth momentum and expects AMX inclusion to increase its visibility and attractiveness to investors. Management reiterates its focus on executing commercial and pipeline catalysts as it aims to develop further as a global rare disease company.

Insights

Equity indices & capital markets analyst

Index promotion signals improved scale and liquidity but is mainly reputational.

Pharming Group is moving from the Euronext AScX small-cap index to the AMX mid-cap index effective September 22, 2025. AMX membership is based on free-float market capitalization and liquidity, so this promotion indicates that Pharming now ranks among the 25 mid-cap names meeting those criteria on Euronext Amsterdam.

The company links this move to what it calls strong financial and pipeline growth momentum. Index inclusion can matter because certain funds track or benchmark against the AMX, which may support trading activity in the shares, though the extent depends on index-linked investor demand.

Management also highlights greater visibility and investor appeal from AMX inclusion and ties this to its broader strategy in rare diseases. Future company disclosures on commercial progress and pipeline milestones will provide more concrete evidence of how this larger-cap status aligns with operational performance.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Pharming Group N.V. announce in this Form 6-K?

Pharming Group N.V. reported that it has been promoted from the Euronext AScX (Small Cap) index to the Euronext AMX (MidCap) index, returning to the AMX after the latest index review.

When does Pharming Group’s inclusion in the Euronext AMX index become effective?

Pharming Group’s promotion to the Euronext AMX (MidCap) index is effective from September 22, 2025, following Euronext Amsterdam’s index review.

On what basis was Pharming Group moved to the Euronext AMX index?

Euronext Amsterdam states that the AMX index comprises 25 companies based on free-float market capitalization and liquidity, and Pharming’s promotion reflects its position under these criteria.

How does Pharming Group describe the significance of its AMX promotion?

Pharming Group says that inclusion in the AMX mid-cap index reflects its financial and pipeline growth momentum and expects it will increase the company’s visibility and attractiveness to investors.

What is Pharming Group N.V.’s core business focus?

Pharming Group N.V. is a global biopharmaceutical company focused on transforming the lives of patients with rare, debilitating, and life-threatening diseases through a portfolio of innovative small-molecule and biologic medicines.

On which exchanges is Pharming Group N.V. listed?

Pharming Group N.V. is listed on Euronext Amsterdam under the symbol PHARM and on the Nasdaq under the symbol PHAR.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 09/10/2025 - 06:15 AM EDT Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the Month of September 2025

Commission File Number: 001-39822

Pharming Group N.V.

(Exact Name of Registrant as Specified in Its Charter)

Darwinweg 24

2333 CR Leiden

The Netherlands

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

Furnished as Exhibit 99.1 to this Report on Form 6-K is a press release of Pharming Group N.V., or the Company, dated September 10, 2025.

EXHIBIT INDEX

Exhibit No.						Description
99.1						Pharming Group promoted to the Euronext AMX® index

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

			Pharming Group N.V.
			By:			/s/ Fabrice Chouraqui
						Name:			Fabrice Chouraqui
						Title:			CEO

Date: September 10, 2025

Pharming Group promoted to the Euronext AMX® index

Leiden, the Netherlands, September 10, 2025: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM / Nasdaq: PHAR) today announced that it has been promoted from the Euronext AScX® (Small Cap) to the AMX® (MidCap) index, effective from September 22, 2025.

Euronext Amsterdam announced the results of its review of the AMX index, which comprises 25 companies based on free-float market capitalization and liquidity. This marks Pharming’s return to the AMX index, reflecting the Company’s strong growth momentum.

Fabrice Chouraqui, Chief Executive Officer, commented:

“Pharming’s inclusion in the AMX mid cap index reflects our financial and pipeline growth momentum. It will further increase our visibility and attractiveness to investors. Looking forward, we remain focused on executing on our significant commercial and pipeline catalysts and continuing to develop into a leading global rare disease company.”

About Pharming Group N.V.

Pharming Group N.V. (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. We are commercializing and developing a portfolio of innovative medicines, including small molecules and biologics. Pharming is headquartered in Leiden, the Netherlands, and has employees around the globe who serve patients in over 30 markets in North America, Europe, the Middle East, Africa, and Asia-Pacific.

For more information, visit www.pharming.com and find us on LinkedIn.

Forward-looking Statements

This press release may contain forward-looking statements. Forward-looking statements are statements of future expectations that are based on management’s current expectations and assumptions and involve known and unknown risks and uncertainties that could cause actual results, performance, or events to differ materially from those expressed or implied in these statements. These forward-looking statements are identified by their use of terms and phrases such as “aim”, “ambition”, ‘‘anticipate’’, ‘‘believe’’, ‘‘could’’, ‘‘estimate’’, ‘‘expect’’, ‘‘goals’’, ‘‘intend’’, ‘‘may’’, “milestones”, ‘‘objectives’’, ‘‘outlook’’, ‘‘plan’’, ‘‘probably’’, ‘‘project’’, ‘‘risks’’, “schedule”, ‘‘seek’’, ‘‘should’’, ‘‘target’’, ‘‘will’’ and similar terms and phrases. Examples of forward-looking statements may include statements with respect to timing and progress of Pharming's preclinical studies and clinical trials of its product candidates, Pharming's clinical and commercial prospects, and Pharming's expectations regarding its projected working capital requirements and cash resources, which statements are subject to a number of risks, uncertainties and assumptions, including, but not limited to the scope, progress and expansion of Pharming's clinical trials and ramifications for the cost thereof; and clinical, scientific, regulatory, commercial, competitive and technical developments. In light of these risks and uncertainties, and other risks and uncertainties that are described in Pharming's 2024 Annual Report and the Annual Report on Form 20-F for the year ended December 31, 2024, filed with the U.S. Securities and Exchange Commission, the events and circumstances discussed in such forward-looking statements may not occur, and Pharming's actual results could differ materially and adversely from those anticipated or implied thereby. All forward-looking statements contained in this press release are expressly qualified in their entirety by the cautionary statements contained or referred to in this section. Readers should not place

undue reliance on forward-looking statements. Any forward-looking statements speak only as of the date of this press release and are based on information available to Pharming as of the date of this release. Pharming does not undertake any obligation to publicly update or revise any forward-looking statement as a result of new information, future events or other information.

For further public information, contact:

Pharming Group, Leiden, the Netherlands

Michael Levitan, VP Investor Relations & Corporate Communications

T: +1 (908) 705 1696

Saskia Mehring, Corporate Communications Manager

T: +31 6 28 32 60 41

E: investor@pharming.com

FTI Consulting, London, UK

Simon Conway/Alex Shaw/Amy Byrne

T: +44 203 727 1000

LifeSpring Life Sciences Communication, Amsterdam, the Netherlands

Leon Melens

T: +31 6 53 81 64 27

E: pharming@lifespring.nl

US PR

Ethan Metelenis

T: +1 (917) 882-9038

E: Ethan.Metelenis@precisionaq.com